1
H NMR spectra were obtained at 300 MHz, 400 MHz, 500 MHz or 600 MHz. 13 C NMR spectra were obtained at 125 MHz or 150 MHz. All results were obtained using Bruker NMR instruments, the models are as follows: Avance III 600, DRX500, Avance III 400, Avance 300. All samples were run at the default number of scans and at 21 °C. Chemical shifts (δ) for 1 H NMR and 13 C NMR are quoted relative to residual signals of the solvent on a parts per million (ppm) scale. Where amide rotamers are the case, and when possible, only the major rotamer has been assigned for chemical shifts, and areas underneath all rotameric peaks have been considered for integration calculations. Coupling constants (J values) are reported in Hertz (Hz) and are reported as J H-H couplings. Infrared spectra were obtained on a Perkin Elmer Spectrum 100 FTIR spectrometer operating in ATR mode. Mass spectra were obtained, for synthetic products, from the UCL mass spectroscopy service on either a Thermo Finnigan MAT900Xp (EI and CI) or Waters LCT Premier XE (ES) mass spectrometer. Melting points were measured with Gallenkamp apparatus and are uncorrected.
UV-Vis spectroscopy
UV-Vis spectroscopy was used to determine protein concentrations and pyridazinedione to antibody ratios (PDAR), using a Varian Cary 100 Bio UV-Visible spectrophotometer operating at 21 °C. Sample buffer was used as blank for baseline correction with extinction coefficients; ε 280 = 215,000 M -1 cm -1 for trastuzumab 18 ε 335 = 9,100 M -1 cm -1 for pyridazinedione scaffolds. A correction factor at 280 nm of 0.25 (at A 335 ) was employed for pyridazinedione scaffolds. PDAR values were calculated as previously described. Di-tert-butyl 1,2-diethylhydrazine-1,2-dicarboxylate (11) 1 To a solution of di-tert-butyl hydrazine-1,2-dicarboxylate (1.16 g, 5.00 mmol) in DMF (20 mL) were added caesium carbonate (3.26 g, 10.0 mmol) and bromoethane (0.70 mL, 14.7 mmol). The heterogeneous mixture was stirred at 21 °C for 24 h. After this time, DMF was removed in vacuo with toluene co-evaporation (3 × 50 mL as an azeotrope). The crude reaction mixture was then dissolved in diethyl ether (100 mL), and then washed with water (3 × 30 mL) and saturated aq. LiCl solution (2 × 30 mL). The organic layer was dried (MgSO 4 ) and concentrated in vacuo to yield di-tertbutyl 1,2-diethylhydrazine-1,2-dicarboxylate 11 (1.21 4,5-Dibromo-1,2-diethyl-1,2-dihydropyridazine-3,6-dione (12) 1 
Preformation of dibromo maleic anhydride in situ:
Dibromomaleic acid 6 (274 mg, 1.00 mmol) was dissolved in AcOH (10 mL) and heated under reflux for 30 min. After this time, di-tert-butyl 1,2-diethylhydrazine-1,2-dicarboxylate 11 (347 mg, 1.20 mmol) was added and the resultant mixture was heated under reflux for a further 4 h. After this time, the reaction mixture was concentrated in vacuo with toluene co-evaporation (3 × 20 mL, as an azeotrope). Purification of the crude residue by flash column chromatography (30% to 70% EtOAc/petrol) yielded 4,5-dibromo-1,2-diethyl-1,2-dihydropyridazine-3,6-dione 12 (267 mg, 0.819 mmol, 82%) as a yellow solid: m.p. 110-115 °C; 
No preformation of anhydride in situ:
To a solution of dibromomaleic acid 6 (274 mg, 1.00 mmol) in AcOH (10 mL) was added di-tert-butyl 1,2-diethylhydrazine-1,2-dicarboxylate 11 (347 mg, 1.20 mmol) and the reaction mixture heated under reflux for 4 h. After this time, the reaction mixture was concentrated in vacuo with toluene coevaporation (3 × 20 mL, as an azeotrope). Purification of the crude residue by flash column chromatography (30% to 70% EtOAc/petrol) yielded 4,5-dibromo-1,2-diethyl-1,2-dihydropyridazine-3,6-dione 12 (210 mg, 0.65 mmol, 65%) as a yellow solid: m.p. 110-115 °C; .
From dibromo maleic anhydride:
To a solution of dibromomaleic anhydride 2 (258 mg, 1.00 mmol) in AcOH (10 mL), was added ditert-butyl 1,2-diethylhydrazine-1,2-dicarboxylate 11 (347 mg, 1.20 mmol) and the reaction mixture heated under reflux for 4 h. After this time, the reaction mixture was concentrated in vacuo with toluene co-evaporation (3 × 20 mL, as an azeotrope). Purification of the crude residue by flash column chromatography (30% to 70% EtOAc/petrol) yielded 4,5-dibromo-1,2-diethyl-1,2-dihydropyridazine-3,6-dione 12 (250 mg, 0.77 mmol, 77%) as a yellow solid: m.p. 110-115 °C; Tri-tert-butyl 2-methylhydrazine-1,1,2-tricarboxylate (S2) 2 To a solution of methylhydrazine S1 (1.00 g, 1.14 mL, 21.7 mmol), NEt 3 (4.34 g, 6.04 mL, 43.4 mmol) and DMAP (260 mg, 2.17 mmol) in CH 2 Cl 2 (75 mL) was added Boc 2 O (18.9 g, 86.6 mmol), and the reaction mixture stirred at 20 °C for 72 h. After this time, the reaction mixture was diluted with H 2 O (80 mL), extracted with EtOAc (3 × 60 mL), and the combined organic layers dried (MgSO 4 ) and concentrated in vacuo. The crude residue was purified by flash column chromatography (20% EtOAc/petrol) to afford tri-tert-butyl 2-methylhydrazine-1,1,2-tricarboxylate S2 (7.43 g, 21.5 mmol, 99%) as a yellowish oil: Di-tert-butyl-1-methylhydrazine-1,2-dicarboxylate (S3) 2 To a solution of methyl hydrazine S1 (1.14 mL, 21.7 mmol) in i-PrOH (16 mL), was added a solution of di-tert-butyl dicarbonate (11.4 g, 52.1 mmol, pre-dissolved in CH 2 Cl 2 (12 mL)) drop-wise over 30 min. The reaction was then stirred at 21 °C for 16 h. After this time, the solvents were then removed in vacuo and the crude residue purified by flash column chromatography (0% to 15% EtOAc/petrol) to afford di-tert-butyl-1-methylhydrazine- 
Di-tert-butyl-1-(3-(tert-butoxy)-3-oxopropyl)-2-methylhydrazine-1,2-dicarboxylate (S6)
To a solution of di-tert-butyl 1-methylhydrazine-1,2-dicarboxylate S3 (3.00 g, 12.2 mmol) in t-BuOH (15 mL) was added 10% NaOH (0.5 mL) and the reaction mixture stirred at 21 °C for 10 min. After this, tert-butyl acrylate (5.31 mL, 36.6 mmol) was added to the solution and the reaction mixture was heated at 60 °C for 24 h. Following this, the solvent was removed in vacuo and the crude residue was dissolved in EtOAc (150 mL) and washed with water (3 × 50 mL). The organic layer was then dried (MgSO 4 ) and concentrated in vacuo. Purification of the crude residue by flash column chromatography (0% to 20% EtOAc/petrol) to afford di-tert-butyl-1-(3-(tert-butoxy)-3-oxopropyl)-2-methylhydrazine-1,2-dicarboxylate S6 (3. 
3-(4,5-Dibromo-2-methyl-3,6-dioxo-3,6-dihydropyridazin-1(2H)-yl) propanoic acid (15)
Dibromomaleic acid 6 (880 mg, 3.06 mmol) was dissolved in AcOH (25 mL) and heated under reflux for 30 min. To this solution, was added di-tert-butyl-1-(3-(tert-butoxy)-3-oxopropyl)-2-methylhydrazine-1,2-dicarboxylate S6 (1.00 g, 2.67 mmol) and the reaction heated under reflux for a further 4 h. After this time, the reaction mixture was concentrated in vacuo with toluene coevaporation (3 × 30 mL, as an azeotrope) and the crude residue purified by flash column chromatography (50% to 100% EtOAc/petrol (1% AcOH)) to afford 3-(4,5-dibromo-2-methyl-3,6-dioxo-3,6-dihydropyridazin-1(2H 
months:
Figure S12
13 C NMR data for 2,5-dioxopyrrolidin-1-yl 3-(4,5-dibromo-2-methyl-3,6-dioxo-3,6-dihydropyridazin-1(2H)-yl) propanoate 16 3 months after synthesis when stored at -20 °C. (3-(2-(2-(3-aminopropoxy) ethoxy)ethoxy)propyl)carbamate (S6) 3 To a solution of 3,3'-((oxybis (ethane-2,1-diyl) )bis(oxy))bis(propan-1-amine) (8.10 g, 37.1 mmol) in 1,4-dioxane (60 mL) was added dropwise di-tert-butyl dicarbonate (1.00 g, 4.60 mmol, pre-dissolved in 1,4-dioxane (25 mL)) over 2 h, ensuring that the temperature did not exceed 21 °C. After this time, the reaction mixture was stirred at 21 °C for a further 30 mins. Following this, the reaction mixture was concentrated in vacuo, the crude residue dissolved in water (50 mL), and the organics extracted into EtOAc (5 × 30 mL). The organics were combined, dried (MgSO 4 ) and concentrated in vacuo to give tert-butyl (3- (2-(2-(3-aminopropoxy) 
tert-Butyl

General PD-Amide coupling protocol:
To a solution of 2,5-dioxopyrrolidin-1-yl 3-(4,5-dibromo-2-methyl-3,6-dioxo-3,6-dihydropyridazin-1(2H)-yl) propanoate 16 (100 mg, 0.221 mmol, pre-dissolved in solvent (10 mL)), was added amine (0.24 mmol) and the reaction mixture was stirred at 21 °C for 16 h. After this time, the reaction was concentrated in vacuo and the crude residue dissolved in CHCl 3 (50 mL), and washed with water (2 × 30 mL) and saturated aq. K 2 CO 3 (30 mL). The organic layer was then dried (MgSO 4 ) and concentrated in vacuo. Purification of the crude residue by flash column chromatography (0% to 10% MeOH/EtOAc) afforded amide products 17a-f as described in the sections below. Detail of the solvent used in each synthesis is indicated below. DiBrPD 17e (2.0 μL, 7.5 mM, 10 mM, 15 mM, 20 mM, 25 mM in DMSO, 15 eq., 20 eq., 30 eq., 40 eq., 50 eq.) was added to solutions of trastuzumab 18 (50 μL, 20 μM) in BBS (25 mM sodium borate, 25 mM NaCl, 0.5 mM EDTA, 2% DMSO, pH 8.0) and the solutions incubated at 4 °C for 1 h. TCEP·HCl (1.0 μL, 10 mM in d.d water at 4 °C, 10 eq.) was added and the solution incubated at 4 °C for 16 h. Excess reagents were removed by ultrafiltration (6 × 10000 MWCO, VivaSpin®¸ GE Healthcare) into PBS (pH = 7.4).
Figure S22
UV-vis spectra of the functional rebridging of trastuzumab 18 with diBrPD 17e at different molar equivalents: 15 eq (PDAR 3.9); 20 eq (PDAR 3.9); 30 eq (PDAR 3.9); 40 eq PDAR (3.6); 50 (PDAR 3.3). PDAR was calculated as previously described.
1
Optimised protocol for the functional bridging of trastuzumab 18 with diBrPDs 17a-e.
Below is a general protocol which was repeated for diBrPDs 17a-e.
DiBrPD 17a-e (2.0, μL, 20 mM in DMSO, 20 eq.) was added to a solution of trastuzumab 18 (50 μL, 40 μM) in BBS (25 mM sodium borate, 25 mM NaCl, 0.5 mM EDTA, 2% DMSO, pH 8.0) and the solution incubated at 4 °C for 1 h. TCEP·HCl (1.0 μL, 20 mM in deionised water at 4 °C, 10 eq.) was added and the solution incubated at 4 °C for 16 h. Excess reagents were removed by ultrafiltration (6 × 10000 MWCO, VivaSpin®¸ GE Healthcare) into PBS (pH = 7.4). All samples were analysed by SDS-PAGE, densitometry, and UV-vis spectrometry. See manuscript Fig. 4a and 4b for SDS-PAGE and densitometry analysis. 
